The Role of Ets Factors in Tumor Angiogenesis

Table 1

Summary of Ets-1 expression, microvessel density (MVD), and prognosis in human cancer.

Tumor type	Number	% Ets-1 positive*	MVD/VEGF	Prognosis**
(1) Ovarian [24]	30	66	increased MVD	2 years survival:
				10% Ets-1 (+); 60% Ets-1 $(-)$
(2) Ovarian [25]	30	50	increased MVD	2 years survival:
				30% Ets-1 (+); 70% Ets-1 $(-)$
(3) Esophageal [26]	55	80	increased MVD	not evaluated
(4) Breast [27]	48	71	increased MVD	not evaluated
(5) Breast [28]	123	62	not evaluated	5 years relapse free survival:
				55% Ets-1 (+); 85% Ets-1 $(-)$
(6) Endometrial [29]	60	66	increased VEGF	not evaluated
(7) Cervical [30]	60	42	increased MVD	2 years survival:
				54% Ets-1 (+); 92% Ets-1 $(-)$
(8) Gastric [31]	102	76	increased MVD	5 years survival:
				67% Ets-1 (+); 89% Ets-1 $(-)$
(9) Colon [32]	95	48	increased MVD	not evaluated
(10) Brain [33]	101	32	not evaluated	not evaluated

“Number” refers to number of patients in the study.
${}_{}{}^{*}\text{\%}$ refers to percent of primary tumors that express Ets-1.
${}_{}{}^{**}\text{\%}$ refers to percent of patients that are relapse free at different time points with primary tumors that expressed Ets-1 (+) or did not express Ets-1 $(-)$.
“MVD/VEGF” refers to evaluation of either VEGF expression or microvascular density (MVD) in the tumors